Clinical Trials Logo

Pelvic Pain clinical trials

View clinical trials related to Pelvic Pain.

Filter by:

NCT ID: NCT00628355 Terminated - Pelvic Pain Clinical Trials

Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment

Start date: February 2008
Phase: Phase 4
Study type: Interventional

Our hypothesis is that with comparison of effectiveness of two most common techniques of treatment for myofascial pain syndrome (injection of local anesthesia and ischemic compression) we could choice the most adequate to treat this disease. This way we could decrease the expenses with medicines, examinations, consultations and the time that women remains without a diagnosis and treatment.

NCT ID: NCT00529386 Terminated - Clinical trials for Chronic Pain Syndrome

Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Start date: January 2006
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of intraprostatic injection of Botox for the treatment of men diagnosed with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS).

NCT ID: NCT00464373 Terminated - Prostatitis Clinical Trials

Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome

BTX-URO-01
Start date: April 2007
Phase: Phase 3
Study type: Interventional

The aim of this randomized placebo-controlled study is to demonstrate the efficiency and safety of the injection of Botulinum Toxin Type A (200 Units) into the external urethral sphincter for the treatment of chronic prostatitis/chronic pelvic pain.

NCT ID: NCT00441935 Terminated - Clinical trials for Urinary Incontinence

InterStim Prospective Database

Start date: April 2004
Phase: N/A
Study type: Observational

The study is to collect information from patient charts and patient questionnaires to evaluate the effects of nerve stimulation therapy on urinary dysfunction.

NCT ID: NCT00301405 Terminated - Pelvic Pain Clinical Trials

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Start date: March 2006
Phase: Phase 2
Study type: Interventional

To determine the efficacy of thalidomide for treatment of the Chronic Pelvic Pain Syndrome (CPPS).

NCT ID: NCT00194623 Terminated - Clinical trials for Chronic Male Pelvic Pain Syndrome

Botox as a Treatment for Chronic Male Pelvic Pain Syndrome

Start date: August 2003
Phase: Phase 4
Study type: Interventional

Chronic pelvic pain syndrome (CPPS) is thought to affect approximately 8% of men aged 18 and older. Patients with this condition experience pain in the perineum, the genitalia, and the rectum. As well, there is associated voiding, sexual, and ejaculatory dysfunction. The impact of patient well-being is thought to be equivalent to patients with congestive heart failure. The etiology of this condition is unknown, thus making treatment very difficult. Researchers have pursued an infectious cause for the disease; however, studies have failed to substantiate this theory. Despite this, the main treatment offered to patients is long-term antibiotic therapy. Results from this treatment modality have been unsatisfactory. Other groups have postulated that the symptoms of CPPS may be secondary to neuromuscular factors. Some studies have demonstrated increases in pelvic muscular tone. Maneuvers such as prostate massage and levator massage have shown some benefit in relieving symptoms. Treatment with alpha-blockers to relax prostate smooth muscle has brought about improvement in a portion of patients. Use of generalized muscle relaxants has produced mediocre results. However, many of these neuromuscular treatments are generalized and do not target the perineal musculature directly. It is theorized that spasm of the perineal muscles triggered by an unknown noxious stimuli (e.g. infection) cause the pain and symptoms of CPPS. At our center, we have performed pilot studies using botulinum toxin A. Four patients were treated with Botox". 100 U were injected in three locations in the midline of the bulbocavernosus muscle. The bulbocavernosus muscle is easily accessible and shares innervation with the pelvic musculature. Patient's response to medication was measured by the NIH Prostatitis pain scale and as well as the University of Washington prostatitis pain scale. All patients reported resolution of symptoms. Remission lasted for duration of 10-12 weeks. No patients reported adverse events. HYPOTHESIS Botulinum toxin A is effective in the treatment of chronic pelvic pain syndrome in men.

NCT ID: NCT00194597 Terminated - Prostatitis Clinical Trials

Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III

Start date: July 2004
Phase: Phase 4
Study type: Interventional

Viagra is a potent 5-PDE inhibitor that causes vasodilation in the penis and, therefore, erection in men with erectile dysfunction. Our hypothesis is that Viagra may improve the symptoms of men with Chronic Pelvic Pain Syndrome based on the following assumptions: Chronic Pelvic Pelvic Syndrome and Interstitial Cystitis involve poorly understood central and peripheral pain sensitization such as are seen in Chronic Sympathetic Dystrophy, also called Chronic Regional Pain Syndrome. This pain may be caused by constricted blood vessels resulting from past stress, injury or trauma Viagra will dilate sympathetically constricted vessels and improve pelvic blood flow in the same manner it does in men with erectile dysfunction. Since men with Chronic Pelvic Pain Syndrome often complain of sexual dysfunction; improving sexual function and, therefore, quality of life may improve overall well being and perception of pain.